Elicio Therapeutics' Lead Pancreatic Cancer Drug Misses Primary Endpoint in Phase 2 Study
ELTX is trading near its 52-week low of $7.37 (35% below the low).
Summary
Elicio Therapeutics' lead pancreatic cancer drug, ELI-002 7P, missed its primary endpoint in a Phase 2 study, though post-hoc analysis identified a subgroup with promising results, leading to a refined Phase 3 development strategy.
Key Events · Product Development and Regulatory · ELTX
-
Phase 2 Primary Endpoint Missed
The AMPLIFY-7P study for ELI-002 7P in adjuvant mutant KRAS-driven pancreatic cancer did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population.
-
Positive Post-Hoc Subgroup Analysis
A post-hoc analysis identified a stronger DFS hazard ratio (HR 0.65, p=0.048) in the R0 (completely resected) patient population, which represented 84% of the study participants.
-
Refined Phase 3 Development Strategy
The company plans a refined Phase 3 study focusing on R0 resected patients and additional ELI-002 7P dosing, subject to financing and FDA alignment.
-
Cash Runway and Financing Needs
Elicio Therapeutics reiterated its cash runway into Q4 2026 and is evaluating strategic financing and partnering opportunities to support future clinical development, especially critical given the 'going concern' warning.
Analysis · ELTX · Life Sciences
Elicio Therapeutics announced that its lead drug candidate, ELI-002 7P, failed to meet the primary endpoint of disease-free survival in its Phase 2 AMPLIFY-7P study for pancreatic cancer. This is a significant setback for the company's clinical development pipeline. While the company highlighted positive signals in a post-hoc analysis of a subgroup (R0 resected patients) and outlined a refined Phase 3 strategy, the initial failure of the primary endpoint is a major negative. This news, which was also reported by Dow Jones Newswires today, comes as the company is already operating under a 'going concern' warning and actively seeking financing, making successful clinical outcomes critical for its future. The refined Phase 3 strategy, focusing on a specific patient population, offers a potential path forward but introduces additional development time and risk.
At the time of this filing, ELTX was trading at $4.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.4M. The 52-week trading range was $7.37 to $16.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.